• Proceedings of the Korean Society of Computer Information Conference
• /
• 2018.07a
• /
• pp.517-518
• /
• 2018

국내 제약 산업은 상위 30대 기업이 전체 생산 매출의 55.1%를 차지하는 불균형적인 구조를 가지고 있으며, 중소업체들은 공급자 과잉의 힘든 상황 속에 처해 있다. 이러한 가운데 중소제약업체를 중심으로 기존 설비를 활용하여 외국 제약회사의 Original 의약품을 복제한 Generic 의약품을 생산하여 납품하는 OEM/ODM 방식의 위탁생산이 증가하고 있다. 또한 글로벌 바이오의약품을 중심으로 CMO(Contract Manufacturing Organization) 생산에 대한 관심이 높아지고 있다. 본 연구에서는 의약품 위 수탁 사업에 있어서 영업사원의 핵심역량인 정보제공, 전문성, 판매기술, 태도 및 관계형성, 업무유연성이 고객 만족에 미치는 영향을 분석하여 CMO업체의 경쟁력 강화를 위한 방안을 제시하고자 한다.

• The Journal of Bigdata
• /
• v.9 no.1
• /
• pp.141-152
• /
• 2024

In the biopharmaceutical contract manufacturing organization (CMO) business, establishing a production schedule that satisfies the due date for various customer orders is crucial for competitiveness. In a CMO process, each order consists of multiple batches that can be allocated to multiple production lines in small batch units for parallel production. This study proposes a meta-heuristic algorithm to establish a scheduling plan that minimizes the total delivery delay of orders in a CMO process with identical parallel machine. Inspired by biological evolution, the proposed algorithm generates random data structures similar to chromosomes to solve specific problems and effectively explores various solutions through operations such as crossover and mutation. Based on real-world data provided by a domestic CMO company, computer experiments were conducted to verify that the proposed algorithm produces superior scheduling plans compared to expert algorithms used by the company and commercial optimization packages, within a reasonable computation time.

• Journal of the Korea Convergence Society
• /
• v.12 no.8
• /
• pp.179-186
• /
• 2021

Among the Covid-19 vaccine platforms, mRNA-platform vaccines are summarized qualitatively in this paper. Manufacturing mRNA vaccines consist of serial processes; the preparation process of DNA template, the transcription of mRNA, nanoemulsion process, and the fill and finish unit combined with formulation stages. It is noticeable that major players are collaborated for producing mRNA vaccines. In particular, the nanoemulsion process is recognized to the key process requiring formulated lipid materials to protect modified mRNA until they arrive in intracellular cytosol. It is known that the nanoemulsion process adapts well-designed microfluidic devices. We expect that the nanoemulsion process will stimulate pharmaceutical industries to develop diverse applications.